Lexicon Realigns Business Around Research and Development Assets, with Focus on Phase 2 LX9211 Neuropathic Pain Program

    NEXT STORY
    Kiniksa Reports Second Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity
    PREV STORY
    Lexicon Pharmaceuticals Enters Into Agreement With TerSera Therapeutics for the Sale of XERMELO
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Calithera Biosciences Announces CB-839 Abstracts Accepted for Presentation at ASCO 2018

    author_avatar
    NASDAQ Market News

    MacroGenics Presents Updated Data from Phase 1 Study of MGD010 at Annual European Congress of Rheumatology (EULAR 2017)

    ROCKVILLE, MD, June 17, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage ...

    author_avatar
    NASDAQ Market News

    Nexstim Has Received Three NBS System Orders in Europe

    author_avatar
    NASDAQ Market News